These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29562514)

  • 1. Amyloid-β and Tau in Alzheimer's Disease: Novel Pathomechanisms and Non-Pharmacological Treatment Strategies.
    Nisbet RM; Götz J
    J Alzheimers Dis; 2018; 64(s1):S517-S527. PubMed ID: 29562514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation.
    Li C; Götz J
    EMBO J; 2017 Nov; 36(21):3120-3138. PubMed ID: 28864542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau aggregation and its interplay with amyloid-β.
    Nisbet RM; Polanco JC; Ittner LM; Götz J
    Acta Neuropathol; 2015 Feb; 129(2):207-20. PubMed ID: 25492702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Amyloid-β and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade.
    Gulisano W; Maugeri D; Baltrons MA; Fà M; Amato A; Palmeri A; D'Adamio L; Grassi C; Devanand DP; Honig LS; Puzzo D; Arancio O
    J Alzheimers Dis; 2018; 64(s1):S611-S631. PubMed ID: 29865055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
    Watanabe K; Uemura K; Asada M; Maesako M; Akiyama H; Shimohama S; Takahashi R; Kinoshita A
    Mol Brain; 2015 Dec; 8(1):82. PubMed ID: 26637371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.
    Xin SH; Tan L; Cao X; Yu JT; Tan L
    Neurotox Res; 2018 Oct; 34(3):733-748. PubMed ID: 29626319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease.
    Gamblin TC; Chen F; Zambrano A; Abraha A; Lagalwar S; Guillozet AL; Lu M; Fu Y; Garcia-Sierra F; LaPointe N; Miller R; Berry RW; Binder LI; Cryns VL
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):10032-7. PubMed ID: 12888622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Untangling amyloid-β, tau, and metals in Alzheimer's disease.
    Savelieff MG; Lee S; Liu Y; Lim MH
    ACS Chem Biol; 2013 May; 8(5):856-65. PubMed ID: 23506614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondria: the common upstream driver of amyloid-β and tau pathology in Alzheimer's disease.
    Silva DF; Esteves AR; Oliveira CR; Cardoso SM
    Curr Alzheimer Res; 2011 Aug; 8(5):563-72. PubMed ID: 21244356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.
    Golde TE
    J Neurochem; 2016 Oct; 139 Suppl 2(Suppl 2):224-236. PubMed ID: 27145445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
    Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
    Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spreading of Pathology in Alzheimer's Disease.
    Lv ZY; Tan CC; Yu JT; Tan L
    Neurotox Res; 2017 Nov; 32(4):707-722. PubMed ID: 28623460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extra-virgin olive oil attenuates amyloid-β and tau pathologies in the brains of TgSwDI mice.
    Qosa H; Mohamed LA; Batarseh YS; Alqahtani S; Ibrahim B; LeVine H; Keller JN; Kaddoumi A
    J Nutr Biochem; 2015 Dec; 26(12):1479-90. PubMed ID: 26344778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Abeta and tau in Alzheimer's disease, an early interim report.
    Golde TE; Petrucelli L; Lewis J
    Exp Neurol; 2010 Jun; 223(2):252-66. PubMed ID: 19716367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease.
    Huang HC; Jiang ZF
    J Alzheimers Dis; 2009; 16(1):15-27. PubMed ID: 19158417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation.
    He Z; Guo JL; McBride JD; Narasimhan S; Kim H; Changolkar L; Zhang B; Gathagan RJ; Yue C; Dengler C; Stieber A; Nitla M; Coulter DA; Abel T; Brunden KR; Trojanowski JQ; Lee VM
    Nat Med; 2018 Jan; 24(1):29-38. PubMed ID: 29200205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.